UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2016


PHARMERICA CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
 


         
Delaware
 
001-33380
 
87-0792558
         
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
         
1901 Campus Place
Louisville, Kentucky 40299
(Address of principal executive offices) (Zip Code)

(502) 627-7000
(Registrant’s telephone number, including area code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 



Item 5.07
Submission of Matters to a Vote of Security Holders.

The 2016 Annual Meeting of Stockholders of PharMerica Corporation (the “Company”) was held on June 17, 2016.

 
1.
The Company’s stockholders approved the election of the following nine directors for a term to expire at the Annual Meeting of Stockholders in 2017. The votes for each director were as follows:

Name
 
For
 
Withheld Authority
 
Broker Non-Votes
Frank E. Collins, Esq.
 
26,685,731
 
114,352
 
2,423,636
W. Robert Dahl, Jr.
 
26,693,231
 
106,852
 
2,423,636
Marjorie W. Dorr
 
26,696,720
 
103,363
 
2,423,636
Thomas P. Gerrity, Ph.D.
 
26,690,992
 
109,091
 
2,423,636
Patrick G. LePore
 
26,693,461
 
106,622
 
2,423,636
Thomas P. Mac Mahon
 
26,691,899
 
108,184
 
2,423,636
Geoffrey G. Meyers
 
26,690,747
 
109,336
 
2,423,636
Robert A. Oakley, Ph.D.
 
26,691,065
 
109,018
 
2,423,636
Gregory S. Weishar
 
26,691,578
 
108,505
 
2,423,636

 
2.
The Company’s stockholders voted upon the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016. The votes on this proposal were as follows:

For
 
Against
 
Abstained
29,131,587
 
78,128
 
14,004

 
3.
The Company’s stockholders voted upon and approved, by advisory vote, the compensation of the Company’s named executive officers. The votes on this proposal were as follows:

For
 
Against
 
Abstained
 
Broker Non-Votes
25,673,570
 
1,096,142
 
30,371
 
2,423,636
 
2

 
4.
The Company’s stockholders voted upon and approved, by advisory vote, a stockholder proposal regarding proxy access. The votes on this proposal were as follows:

For
 
Against
 
Abstained
 
Broker Non-Votes
21,203,097
 
5,577,918
 
19,068
 
2,423,636
 
3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PHARMERICA CORPORATION
   
Date: June 21, 2016
By:
/s/ Thomas Caneris
 
   
Thomas Caneris
 
       
   
Senior Vice President, General Counsel and Secretary